• Mashup Score: 0

    The virtual platform provides convenient, on-demand access to popular scientific sessions from the International Conference, including Year in Review and Core Curriculum sessions; industry presentations from leading companies in the field; and thousands of ePosters highlighting the latest discoveries in pulmonary, critical care, and sleep medicine.

    Tweet Tweets with this article
    • #ATS2022 programming is coming to a close on Friday, June 24. Check out the On-Demand Highlights now, and mark your calendars for #ATS2023: https://t.co/YUuKnt4VSD @gregory1downey https://t.co/kS7frWmsJl

  • Mashup Score: 4

    SAN FRANCISCO — A study of North Philadelphia high school students highlighted the COVID-19 pandemic’s effect on youth vaping patterns and cessation motivation, researchers reported at the American Thoracic Society International Conference.The National Youth Tobacco Survey reported a decrease in current e-cigarette use among high school students from 2019 to 2020 (27.5% vs. 19.6%) due

    Tweet Tweets with this article
    • A study presented at #ATS2022 highlighted the impact that the #COVID19 pandemic had on youth #vaping patterns and cessation motivation @InfectDisNews @Klein_Jeremy https://t.co/J3NeMExstM

  • Mashup Score: 0

    SAN FRANCISCO — Treatment with imatinib resulted in a sustained clinical benefit after 90 days in hospitalized patients with hypoxemic COVID-19, according to results of the CounterCOVID study.At the American Thoracic Society International Conference, Job R. Schippers, MD-PhD candidate for pulmonary medicine at Amsterdam University Medical Center, presented long-term clinical outcomes at 90

    Tweet Tweets with this article
    • Treatment with imatinib resulted in sustained clinical benefit at 90 days in hypoxemic patients with #COVID19, according to results from the CounterCOVID study presented at #ATS2022 @InfectDisNews https://t.co/g8YitDdDWp

  • Mashup Score: 3

    Panelists Erica Farrand, MD; Bridget Collins, MD; Leticia Kawano-Dourado, MD, PhD; Ayodeji Adegunsoye, MD, MS; and Robert W. Hallowell, MD, explained the complexities of the diagnosis and treatment of diseases including pulmonary fibrosis and granulomatous lymphocytic interstitial lung disease, as well as autoimmune rheumatic diseases with pulmonary manifestations.

    Tweet Tweets with this article
    • Presenters discussed interstitial and fibrotic lung diseases during the Pulmonary Clinical Core sessions at #ATS2022. Read a recap in ATS Conference News and watch via On-Demand Highlights: https://t.co/lqJqt8L7OU @ericafarrandMD @bridgetfcollins @leticiakawano @drdayjee https://t.co/MMSoUGYoEx

  • Mashup Score: 1

    SAN FRANCISCO — Inhaled treprostinil significantly improved persistence, adherence and lowered risk for hospitalization compared with iloprost in patients with pulmonary arterial hypertension, researchers reported.“For approved inhaled therapies, we have really two. Inhaled treprostinil is administered four times a day and iloprost must be administered six to nine times. The worry is

    Tweet Tweets with this article
    • Researchers reported inhaled #treprostinil significantly improved persistence, adherence and lowered hospitalization risk vs. iloprost in patients with #PAH in a poster presented at #ATS2022 @CardiologyToday https://t.co/qTIvVSroFZ